scholarly article | Q13442814 |
P50 | author | Paul Ridker | Q7153226 |
Robert J Glynn | Q88253834 | ||
P2093 | author name string | Cushman M | |
Bounameaux H | |||
Shrivastava S | |||
Bauer KA | |||
Goldhaber SZ | |||
Kessler CM | |||
Moll S | |||
P2860 | cites work | Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism | Q34179254 |
Mutation in blood coagulation factor V associated with resistance to activated protein C. | Q34340007 | ||
Thrombophilia, clinical factors, and recurrent venous thrombotic events | Q34419598 | ||
Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology | Q35813336 | ||
Fibrin fragment D-dimer and the risk of future venous thrombosis | Q40625965 | ||
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism | Q44548746 | ||
Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis | Q47351547 | ||
High plasma levels of factor VIII and risk of recurrence of venous thromboembolism | Q48036239 | ||
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia | Q57003501 | ||
The Long-Term Clinical Course of Acute Deep Venous Thrombosis | Q64386235 | ||
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis | Q72414738 | ||
Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study | Q73836575 | ||
D-dimer levels and risk of recurrent venous thromboembolism | Q73864376 | ||
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism | Q74197149 | ||
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study | Q74208452 | ||
P433 | issue | 6 | |
P921 | main subject | (RS)-warfarin | Q407431 |
venous thromboembolism | Q9397786 | ||
P304 | page(s) | 1208-1214 | |
P577 | publication date | 2006-06-01 | |
P1433 | published in | Journal of Thrombosis and Haemostasis | Q6296004 |
P1476 | title | D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. | |
P478 | volume | 4 |
Q56978729 | Age and gender specific cut-off values to improve the performance of D-dimer assays to predict the risk of venous thromboembolism recurrence |
Q24633053 | Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
Q35987865 | Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism |
Q83363859 | Can anticoagulant treatment be tailored with biomarkers in patients with venous thromboembolism? |
Q53672029 | Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study. |
Q36947358 | D-dimer level and the risk for thrombosis in systemic lupus erythematosus |
Q34418291 | Disease risk factors identified through shared genetic architecture and electronic medical records |
Q57616514 | Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis |
Q38777416 | Economic evaluation of strategies for restarting anticoagulation therapy after a first event of unprovoked venous thromboembolism. |
Q36063535 | Epidemiology and risk factors for venous thrombosis |
Q38263114 | How D-dimer assay can be useful in deciding the duration of anticoagulation after venous thromboembolism: a review |
Q33804430 | Kidney function and multiple hemostatic markers: cross sectional associations in the multi-ethnic study of atherosclerosis |
Q37806826 | Long-term Anticoagulation for Venous Thromboembolism: Duration of Treatment and Management of Warfarin Therapy |
Q36718482 | Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach |
Q89468101 | Mechanisms and mitigating factors for venous thromboembolism in chronic kidney disease: the REGARDS study |
Q47959251 | Optimal long-term pharmacological treatment of patients with venous thromboembolism that was unprovoked or associated with weak risk factors |
Q47923995 | Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). |
Q36079864 | Prospective study of plasma D-dimer and incident venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study |
Q26826847 | Recurrent venous thromboembolism: what is the risk and how to prevent it |
Q34153343 | Risk assessment for recurrent venous thrombosis |
Q30889099 | Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data |
Q34603112 | Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis |
Q36986116 | Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis |
Q84110126 | The diagnostic yield of D-Dimer in relation to time from symptom onset in patients evaluated for venous thromboembolism in the emergency medicine department |
Q51650332 | Thrombophilia: 2009 update. |
Q38365992 | Thrombophilia: clinical-practical aspects |
Q37419797 | Unanswered questions in venous thromboembolism |
Q84796444 | Update in general internal medicine |
Q51767834 | Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. |